登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C19H12O8
化学文摘社编号:
分子量:
368.29
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
diacerein
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O
InChI
1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)
InChI key
TYNLGDBUJLVSMA-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Diacerein EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 双醋瑞因
signalword
Warning
hcodes
pcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
N G de Isla et al.
Bio-medical materials and engineering, 18(1 Suppl), S99-104 (2008-05-06)
Osteoarthritis (OA) is a progressive joint disease which represents a combination of several disorders leading to cartilage degradation. The production of nitric oxide (NO) by iNOS, which is stimulated by proinflammatory mediators, is involved in cartilage catabolism and should therefore
G Falgarone et al.
Current rheumatology reports, 3(6), 479-483 (2001-11-16)
This paper reviews the most recent clinical and experimental studies on diacerein, both of which are under investigation. Diacerein could be a disease-modulating agent in osteoarthritis because structural benefits have been reported in recent trials. Moreover, after an empirical use
D Provvedini et al.
Presse medicale (Paris, France : 1983), 31(39 Pt 2), 4S13-4S15 (2003-01-09)
SYMPTOMATIC EFFECTS OF DIACEREIN: Data obtained from several clinical trials have demonstrated that relief of joint pain obtained with the interleukin-1 inhibitor diacerein is comparable with that observed with non-steroidal anti-inflammatory drugs (NSAIDS) after four to six weeks of treatment
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0001595 | 04061833808818 |